Volver

Tempus AI, Inc. Class A Common Stock

Ticker: TEM ISIN: US88023B1035
Añadir al portafolio Análisis de cartera en 2min
Stock Mid-cap
Capitalización
8,78 MM $
Forward P/E
0,00
Profit margin
-19,27%
Revenue growth QoQ
83,00%
66,17 $ -8,97%
Precio a fecha de 2026-08-24 · NASDAQ

Rendimiento por período

Rendimientos acumulados
1 Month +54,21%
6 Months +15,50%
1 Year -12,82%
Since inception +25,44% p.a.+64,40%
Rendimientos por año
YTD +12,06%
2025 +74,91%

Key stats

Market cap
8,78 MM
52-week range
36.22 - 104.32
50-day MA
57,60
200-day MA
69,23
Section 1

Business overview

Company profile data from fundamentals.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Sector Healthcare
Industry Health Information Services
Country United States
Exchange NASDAQ
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE -89,48%
ROA -9,66%
Profit margin -19,27%
Operating margin -16,70%
Revenue/share TTM 7,30
Revenue TTM 1,27 MM
EBITDA -171,51 M
Gross profit TTM 797,90 M

Valuation

Trailing P/E 0,00
Forward P/E 0,00
P/B 17,09
P/S 6,91
EV/EBITDA 0,00
EV/Revenue 7,05
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) -0,42
Quarterly earnings growth 0,00%
Revenue TTM 1,27 MM
Section 4

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 4,10
Short % of float 17,99%

Details

Instrument metadata and source update timestamps.

Symbol TEM
Name Tempus AI, Inc. Class A Common Stock
Asset type STOCK
Exchange NASDAQ
Currency USD
ISIN US88023B1035
Country USA
Code + exchange TEM.NASDAQ
Fundamentals updated 2026-03-25

La información proporcionada en esta plataforma es solo para fines informativos y no debe considerarse como asesoramiento financiero o de inversión. Insightfolio no ofrece asesoramiento financiero, recomendaciones personalizadas ni orientación sobre la compra, tenencia o venta de activos financieros. Las herramientas y contenidos son únicamente educativos y no están adaptados a las circunstancias, necesidades financieras u objetivos personales.

Insightfolio no asume ninguna responsabilidad por la precisión, integridad o fiabilidad de la información presentada. Es responsabilidad exclusiva de los usuarios verificar la información y tomar decisiones independientes basándose en su propia investigación y consideración. El uso de esta plataforma no reemplaza la consulta con profesionales financieros cualificados.

Invertir implica riesgos. Los usuarios deben ser conscientes de que el valor de las inversiones puede fluctuar y que los rendimientos pasados no son garantía de resultados futuros. Las decisiones de inversión deben basarse en objetivos financieros personales, tolerancia al riesgo y una evaluación independiente de la información relevante.

Insightfolio no respalda ni garantiza la idoneidad de ningún producto financiero, valor o estrategia en particular. Cualquier proyección, pronóstico o escenario hipotético presentado en la plataforma es solo ilustrativo y no constituye una garantía.

Al acceder a los servicios, información o contenido ofrecido por Insightfolio, los usuarios reconocen y aceptan los términos de este aviso legal. Si no estás de acuerdo con estos términos, por favor no uses nuestra plataforma.

Logotipos de instrumentos proporcionados por Elbstream.